Sunday, December 3, 2023
Home Health Anti-PD1 Drug-resistant Tumor Models:Three Types of Drug Models and Application Scenarios

Anti-PD1 Drug-resistant Tumor Models:Three Types of Drug Models and Application Scenarios

The PD-1/PD-L1 axis is a well-known immune checkpoint, High activity within the PD-1/ PD-L1 axis promotes T cell dysfunction. Great progresses are made in recent years to use PD-1/PDL1 blockade therapy in cancer treatment. Studies have shown that primary resistance to anti-PD1 therapies is common, affecting up to 60% of patients in some cancer. Furthermore, it is now becoming apparent that initial responses observed among some patients can be undone by their development of acquired resistance to anti-PD1 therapies. Given the common problem, GemPharmatech has successfully developed a variety of anti-PD1 resistant model.

1.Keytruda-induced resistance model

Through inoculating anti-PD1 drug-sensitive tumor cell lines CT26 and MC38 on hPD1 target humanized mice, followed by induction with Keytruda, drug-resistant tumor strains were isolated and established. These resistant strains were then re-implanted into mice and subjected to drug treatment induction. After multiple cycles of this process, drug-resistant strains were eventually obtained.

Fig1. Keytruda-induced drug resistance model in CT26

Fig2. Keytruda-induced drug resistance model in MC38

2.MHC-I deficiency drug-resistant model

MHC-I (major histocompatibility complex class I), mainly mediates the process of endogenous antigen presentation, and knockout of B2M protein results in MHC-I deficiency.

Fig3. Keytruda efficacy test in subcutaneous tumor-bearing CT26 and CT26-mB2m KO models of BALB/c-hPD1 mice

  1. Natural drug-resistant strain model

KPC: TIL analysis

Fig4. Subcutaneous inoculation of KPC cell line in C57BL/6J mice

Pan02: Drug efficacy data

Fig5. Subcutaneous inoculation of Pan02 cell line in C57BL/6J mice

B16F10: Drug efficacy data and TIL analysis

Fig6. Subcutaneous inoculation of B16F10 cell line in B6-hPD1/hLAG3 mice

LLC: TIL analysis

Fig7. Subcutaneous inoculation of LLC cell line in C57BL6-hPD1 mice

4T1: Drug efficacy data and TIL analysis

Fig8. Subcutaneous inoculation of 4T1 cell line in Balb/c-hPD1hTIGIT mice

EMT6: Drug efficacy data and TIL analysis 

Fig9. Subcutaneous inoculation of EMT6 cell line in BALB/c-hPDL1 mice

RENCA: Drug efficacy data and TIL analysis

Fig10. Subcutaneous inoculation of RENCA cell line in BALB/c-hPD1/hTIGIT mice

Characteristics and Application Scenarios of Various Drug Resistance Models

Learn more:

Most Popular

From Arcade to Boardroom: Applying Gaming Principles in Business Leadership

In the dynamic landscape of modern business, leaders are constantly on the lookout for innovative approaches to enhance their strategic thinking, team collaboration, and...

Open Car Shipping: Cost-Effective and Common

Open car shipping is the most common and cost-effective method of transporting vehicles. This service involves loading your vehicle onto an open carrier and...

Keep Your Family Healthy With These Helpful Tips

Every parent wants their family to be healthy. Parents put effort into bringing up their kids in a healthy environment and nutritious food. However,...

The Art of Clean: Mobile Wash Solutions for Sparkling Decks in Toronto

In the vibrant city of Toronto, where urban life meets natural beauty, homeowners take pride in their outdoor spaces. A well-maintained deck is not...